Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed or recurrent supratentorial primary or metastatic malignant brain tumor Measurable disease by MRI or CT scan Candidate for surgical resection Extension of tumor no more than 1.0 cm beyond the margin of the surgical cavity Demonstrated reactivity of tumor cells with tenascin by immunohistology with either a polyclonal rabbit antibody or the monoclonal mouse antibody No infratentorial tumors, diffusely infiltrating tumors, tumors with subependymal spread, or multifocal tumors PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 50-100% Life expectancy: Not specified Hematopoietic: Absolute neutrophil count greater than 1000/mm^3 Platelet count greater than 100,000/mm^3 Hepatic: Bilirubin less than 1.5 mg/dL Alkaline phosphatase less than 1.5 times normal SGOT less than 1.5 times normal Renal: Creatinine less than 1.2 mg/dL Other: Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks since prior chemotherapy, unless unequivocal evidence of progression Endocrine therapy: Concurrent corticosteroids allowed, but must be on stable dose for at least 1 week Radiotherapy: At least 3 months since prior radiotherapy to site of measurable disease in the CNS Surgery: See Disease Characteristics